INO / Inovio Pharmaceuticals (INO) Reports Q1 Loss, Misses Revenue Estimates

Biotechnology company Inovio saw its shares jump after the US FDA communicated that data from Inovio completed Phase 1/2 trial of INO-3107 for treatin more_horizontal

Inovio Pharmaceuticals, Inc. (NASDAQ:INO ) H.C. Wainwright 25th Annual Global Investment Conference Call September 12, 2023 4:30 PM ET Company Partici more_horizontal

We gave Inovalis REIT our first review in December 2022. We noted that the NAV estimates were optimistic and crystallization of that value was improba more_horizontal

Inovio Pharmaceuticals, Inc. (NASDAQ:INO ) Jefferies Healthcare Conference 2023 June 9, 2023 8:00 PM ET Company Participants Jacqueline Shea - Preside more_horizontal

INOVIA (INO) shares surge 12% in the after-market hours, when its drug for treating a rare respiratory tract disease, INO-3107, receives orphan drug d more_horizontal

Inovio Pharmaceuticals, Inc. (NASDAQ:INO ) 2023 RBC Capital Markets Global Healthcare Conference May 16, 2023 4:05 PM ET Company Participants Greg Ren more_horizontal

Inovio (INO) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stoc more_horizontal

Inovio Pharmaceuticals (INO) came out with a quarterly loss of $0.16 per share versus the Zacks Consensus Estimate of a loss of $0.14. This compares t more_horizontal